Drug Trial Radar · NCT06570031
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Nov 9, 2021
Primary completion
Apr 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, non-controlled, phase I study to investigate the tolerability and safety of ONO-4578 used in combination with standard-of-care letrozole and a CDK4/6 inhibitor (palbociclib or Abemaciclib) as first-line endocrine therapy in postmenopausal patients with metastatic or recurrent hormone receptor-positive, HER2-negative breast cancer.
Conditions
- Hormone Receptor-positive Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer
Interventions
ONO-4578Drug
Specified dose on specified days
letrozoleDrug
Specified dose on specified days
PalbociclibDrug
Specified dose on specified days
abemaciclibDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Through study completion, an average of 4 year
- Serious adverse eventsTime frame: Through study completion, an average of 4 year
- Dose-limiting toxicity (Tolerability Confirmation part only)Time frame: 28 days
- Laboratory abnormality profile of Drugs as measured by incidence and severity of clinical laboratory abnormalitiesTime frame: Through study completion, an average of 4 year
- Body temperatureTime frame: Through study completion, an average of 4 year
- Pulse rateTime frame: Through study completion, an average of 4 year
- Systolic/diastolic blood pressureTime frame: Through study completion, an average of 4 year
- Saturation of Percutaneous Oxygen (SpO2)Time frame: Through study completion, an average of 4 year
- WeightTime frame: Through study completion, an average of 4 year
- Eastern Cooperative Oncology Group Performance StatusTime frame: Through study completion, an average of 4 year
- Chest X-rayTime frame: Through study completion, an average of 4 year
- CT scanTime frame: Through study completion, an average of 4 year
- 12-lead electrocardiography (Heart rate)Time frame: Through study completion, an average of 4 year
- 12-lead electrocardiography (PR interval)Time frame: Through study completion, an average of 4 year
- 12-lead electrocardiography (RR interval)Time frame: Through study completion, an average of 4 year
- 12-lead electrocardiography (QRS width)Time frame: Through study completion, an average of 4 year
- 12-lead electrocardiography (QT interval)Time frame: Through study completion, an average of 4 year
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Chiba Cancer Center
Chiba, Chiba, Japan
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
Saitama Cancer Center
Shinden, Saitama, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital Of JFCR
Koto-ku, Tokyo, Japan
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.